Arcus Biosciences (RCUS) said Tuesday that it has priced an underwritten offering of 13.6 million shares at $11 per share, for total proceeds of $150 million.
The company said it is selling all of the shares in the offering, which is set to be completed on Wednesday.
Arcus said the proceeds from the offering will be used to fund ongoing research and development, as well as for other general corporate purposes.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。